Glycan-based high-affinity ligands for toxins and pathogen receptors
✍ Scribed by Ashish A. Kulkarni; Alison A. Weiss; Suri S. Iyer
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 798 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0198-6325
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Glycans decorate over 95% of the mammalian cell surface in the form of glycolipids and glycoproteins. Several toxins and pathogens bind to these glycans to enter the cells. Understanding the fundamentals of the complex interplay between microbial pathogens and their glycan receptors at the molecular level could lead to the development of novel therapeutics and diagnostics. Using Shiga toxin and influenza virus as examples, we describe the complex biological interface between host glycans and these infectious agents, and recent strategies to develop glycan‐based high‐affinity ligands. These molecules are expected to ultimately be incorporated into diagnostics and therapeutics, and can be used as probes to study important biological processes. Additionally, by focusing on the specific glycans that microbial pathogens target, we can begin to decipher the “glycocode” and how these glycans participate in normal and aberrant cellular communication. © 2010 Wiley Periodicals, Inc. Med Res Rev, 30, No. 2, 327–393, 2010
📜 SIMILAR VOLUMES
Humans have sought inspiration from nature since the beginning of recorded history. For today's scientists, biological systems are replete with molecular recognition events of awe-inspiring specificity. Contrary to amino and nucleic acids, carbohydrates tend to behave as elusive ligands toward their
## Abstract The reported competition STD NMR method combines saturation transfer difference (STD) NMR with competition binding experiments to allow the detection of high‐affinity ligands that undergo slow chemical exchange on the NMR time‐scale. With this technique, the presence of a competing high
## Abstract In this study, we evaluated the applicability of ligand‐based and structure‐based models to quantitative affinity predictions and virtual screenings for ligands of the β~2~‐adrenergic receptor, a G protein‐coupled receptor (GPCR). We also devised and evaluated a number of consensus mode